Zentalis Pharmaceuticals ...
2.77
0.13 (4.73%)
At close: Jan 15, 2025, 12:47 PM
undefined%
Bid 2.76
Market Cap 197.41M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.5
PE Ratio (ttm) -1.11
Forward PE n/a
Analyst Buy
Ask 2.77
Volume 812,082
Avg. Volume (20D) 1,330,350
Open 2.77
Previous Close 2.65
Day's Range 2.71 - 2.88
52-Week Range 2.41 - 18.07
Beta undefined

About ZNTL

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 3, 2020
Employees 124
Stock Exchange NASDAQ
Ticker Symbol ZNTL

Analyst Forecast

According to 8 analyst ratings, the average rating for ZNTL stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 206.86% from the latest price.

Buy 50.00%
Hold 50.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Zentalis Pharmaceuticals Inc. is scheduled to release its earnings on Feb 25, 2025, before market opens.
Analysts project revenue of $36.16M, reflecting a n/a YoY growth and earnings per share of -3, making a 294.74% increase YoY.
5 days ago · Source
-1.08%
Zentalis Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription
2 months ago · Source
-12.15%
Zentalis Pharmaceuticals shares are trading lower after Guggenheim cut its price target on the stock from $12 to $8.